Advertisement
Amgen
Subscribe to Amgen

The Lead

Bayer and Onyx Pharmaceuticals’ Phase 3 Trial of NEXAVAR Misses Study Goals

July 25, 2014 8:26 am | News | Comments

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

FDA Reviewing What Could Be First Biosimilar Drug

July 24, 2014 3:51 pm | News | Comments

Five years after Congress passed a law allowing biosimilars, for the first time the FDA has...

Amgen Names Senior Vice President, Global Regulatory Affairs And Safety

May 13, 2014 8:25 am | News | Comments

Amgen has announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior...

Amgen and AstraZeneca Announce Positive Results from Phase 3 Psoriasis Study

May 12, 2014 8:52 am | News | Comments

Amgen and AstraZeneca announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in...

View Sample

FREE Email Newsletter

Amgen Misses First Quarter Goals as Higher Costs Cut Profit

April 23, 2014 8:10 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Despite higher sales, Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply. Last year's quarter also gained from a tax benefit. The company missed Wall Street's expectations for both earnings per share and revenue, sending down its shares.

Studies Find New Drugs Greatly Lower Cholesterol

March 29, 2014 3:31 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can't tolerate or don't get enough help from Lipitor and other statin drugs that have been in use for decades.  

Pharma Data Play Larger Role in Olympic Drug Tests

February 10, 2014 8:34 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets.     

Advertisement

Amgen Fourth Quarter Profit Leaps 30% on Higher Sales

January 28, 2014 7:13 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Amgen Inc.'s fourth-quarter profit jumped 30 percent mainly due to a tax benefit from prior-year audits, an acquisition and higher sales for nearly all its drugs — much of it from price hikes. The world's biggest maker of biologic drugs said Tuesday that net income was $1.02 billion, or $1.33 per share, up from $788 million or $1.01 per share, a year earlier.

Amgen, Illumina Team on Personalized Medicine Test

January 16, 2014 8:43 am | News | Comments

Biotech drugmaker Amgen and Illumina, a maker of genetic testing equipment, said Wednesday they are developing a test that will identify patients who might be helped by Amgen's colon cancer drug Vectibix.       

Amgen CFO Stepping Down

January 10, 2014 8:00 am | News | Comments

Amgen said Thursday that Chief Financial Officer Jonathan Peacock is leaving the company to pursue other opportunities.                      

Amgen 3Q Profit Jumps 24% on Stronger Sales

October 23, 2013 8:34 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Amgen has announced that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits, one of them helped by a big government purchase.   

Amgen Acquires Filgrastim Franchise Rights from Roche In 100 Markets

October 22, 2013 9:15 am | News | Comments

Amgen today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014.     

Advertisement

Earnings Preview: Amgen to Report 3Q Results

October 18, 2013 7:52 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Amgen will focus on the integration and strategy behind its acquisition of Onyx Pharmaceuticals, which makes two cancer drugs and has others in testing, when it reports third-quarter results late Tuesday.       

Amgen and ShanghaiTech University Announce Plans for Amgen China R&D Center

September 25, 2013 8:21 am | News | Comments

Amgen and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. This agreement includes plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University.

Amgen Buying Cancer Drug Maker Onyx for $10.4B

August 25, 2013 6:46 pm | by The Associated Press | News | Comments

Amgen will buy cancer drug maker Onyx Pharmaceuticals for about $10.4 billion in cash in a deal that will add several cancer drugs to Amgen's stable and add to its pipeline of new drugs. Amgen Inc. said Sunday it will acquire Onyx for $125 per share, and it expects to complete...

Amgen Second Quarter Net Dips on Higher Research, Other Costs

July 31, 2013 8:09 am | by LINDA A. JOHNSON,AP Business Writer | News | Comments

Amgen said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines. However, the results from world's biggest biotech drugmaker soared above Wall Street expectations and it raised its profit forecast significantly.

Earnings Preview: Amgen to Report on Research

July 26, 2013 6:15 pm | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | Comments

Biotech drugmaker Amgen Inc. will review sales of key drugs and lots of recent research results, both for experimental drugs and one already on the market, when it reports second-quarter results after the stock market closes Tuesday. Amgen executives likely will note a new...

Advertisement

Amgen and Servier to Collaborate on Cardiovascular Products

July 10, 2013 8:23 am | News | Comments

Amgen and Servier have announced a new collaboration agreement leveraging each company's commitment to cardiovascular disease.                     

Onyx Confirms, Rejects Amgen's $120-Per-Share Bid

July 1, 2013 8:27 am | News | Comments

Onyx Pharmaceuticals on Sunday confirmed that it received an unsolicited takeover bid from Amgen Inc. for $120 per share. But the drug developer says it rejected the offer, because it "significantly undervalued" the company. Onyx also said that other companies have expressed interest in a buyout.

FDA Backs New for Amgen Drug for Rare Bone Tumors

June 14, 2013 8:29 am | by The Associated Press | News | Comments

Amgen Inc. said yesterday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.

Astellas, Amgen to Form Joint Venture in Japan

May 29, 2013 7:56 am | News | Comments

Tokyo-based Astellas Pharma Inc. said today it will form a joint venture with major U.S. biotechnology company Amgen Inc. to develop and market drugs in Japan. The new company will start business operations in October to develop five drugs, including for gastric cancer and osteoporosis, under a plan to launch drug sales in 2016.

Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic Partners

May 17, 2013 8:16 am | News | Comments

Atlas Venture has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners.

Earnings Preview: Amgen Reports 1Q results Tuesday

April 19, 2013 8:01 am | by LINDA A. JOHNSON,AP Business Writer | News | Comments

Biotech drugmaker Amgen Inc. will focus on recent results on a key experimental melanoma drug, testing of other drugs and revenue from its top-selling drugs when it reports first-quarter results after the stock market closes Tuesday. The world's biggest biotech company will discuss promising preliminary results in a late-stage study of its experimental drug for the deadly skin cancer melanoma

Amgen to Pay $25M to Resolve Kickback Case

April 16, 2013 6:37 pm | by The Associated Press | News | Comments

The U.S. Department of Justice said Tuesday that biotech drugmaker Amgen Inc. will pay $24.9 million to resolve claims it paid kickbacks to increase sales of its anemia drug Aranesp. The Justice Department said Amgen paid kickbacks to Omnicare Inc. and PharMerica Corp., which sell drugs to...

Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma

March 20, 2013 7:52 am | News | Comments

Amgen today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).

Drugmakers, Interpol Ramp Up Fight Against Fakes

March 12, 2013 1:01 am | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | Comments

More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...

FDA Halts Amgen Study After Teen Patient Death

February 27, 2013 7:55 am | News | Comments

Federal health regulators have halted Amgen's studies of its drug Sensipar after the death of a 14-year-old patient in a company trial. The Food and Drug Administration said Tuesday it is still gathering information about the death, but has shut down all studies of the drug in children.

Amgen Rises on Recall of Affymax Anemia Drug

February 26, 2013 8:07 am | News | Comments

Shares of Amgen Inc. rose Monday after a drug that competes with Amgen's anemia treatment Aranesp and Epogen was taken off the market because of severe allergic reactions and deaths in some patients. Affymax Inc. and Takeda Pharmaceutical Co. issued a recall of their anemia drug Omontys on Saturday, saying dialysis centers should stop using it.

Selexis Announces Expansion of R&D License Agreement with Amgen

February 20, 2013 7:56 am | News | Comments

Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line for research and development.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading